ACADIA Pharmaceuticals (ACAD) investor relations material

Commercial performance and strategy

• NUPLAZID has seen accelerated growth, with 20% year-over-year increase in new prescriptions last quarter, driven by education and targeted sales efforts.

• DAYBUE, the only approved Rett syndrome treatment, maintains over 50% persistency at 12 and 18 months, with 70% of patients on therapy for over a year.

• Launch of DAYBUE STIX, a new powder formulation, has shifted prescription trends, with 60% of June prescriptions for the new version.

• Expanded sales teams for both products have increased reach and uptake, especially among previously untreated or disengaged patients.

• Education and advocacy remain central to commercial success, particularly in rare diseases.

Market dynamics and competition

• Increased awareness campaigns, including celebrity partnerships, have tripled recognition of Parkinson's disease psychosis.

• New entrants in Parkinson's disease and potential gene therapies in Rett syndrome are seen as positive for overall disease awareness and patient care.

• DAYBUE is expected to remain foundational in Rett syndrome care, even as gene therapies emerge, due to its established role and reversibility.

International expansion

• Positive CHMP opinion for DAYBUE in Europe, with launch planned in Germany first and broader rollout based on country-specific reimbursement.

• European Rett syndrome population is estimated at 8,000–12,000, larger than the U.S., presenting significant growth potential.

• Adapted regulatory strategy and advocacy engagement turned a negative CHMP opinion into a positive one, with anticipated label differences from the U.S.

• Japan strategy focuses on partnerships to facilitate DAYBUE access, marking the company's first entry into the Japanese market.